We are live on ! Find out more
SLS icon

SELLAS Life Sciences

28 hedge funds and large institutions have $2.68M invested in SELLAS Life Sciences in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,158% more call options, than puts

Call options by funds: $700K | Put options by funds: $31K

0% less ownership

Funds ownership: 0.01%0.01% (-0%)

18% less funds holding

Funds holding: 3428 (-6)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

41% less capital invested

Capital invested by funds: $4.57M → $2.68M (-$1.89M)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

Holders
28
Holders Change
-6
Holders Change %
-17.65%
% of All Funds
0.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
6
Reduced
8
Closed
10
Calls
$700K
Puts
$31K
Net Calls
+$669K
Net Calls Change
-$504K

SLS Hedge Fund Activity: Q3 2017 in Review

28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q3 2017, worth a combined $2.68M — down 41% from $4.57M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of SLS and 5 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $242K. The largest seller was Element Capital Management, exiting entirely with an estimated $93K sold.

  • 28 institutional investors held SELLAS Life Sciences (SLS) as of Q3 2017, down from 34 in Q2 2017.
  • Funds reported $2.68M of SELLAS Life Sciences stock for Q3 2017, down 41% quarter-over-quarter.
  • 5 funds opened new SELLAS Life Sciences positions in Q3 2017 and 10 closed out, a net change of -5 holders.
  • The largest SELLAS Life Sciences buyer in Q3 2017 was Renaissance Technologies, an estimated $242K added.
  • The largest SELLAS Life Sciences seller in Q3 2017 was Element Capital Management, an estimated $93K sold.

Based on aggregated 13F filings for Q3 2017.